HSBC Holdings
PCVX icon

HSBC Holdings’s Vaxcyte PCVX Stock Holding History

HSBC Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Buy
4,151
+159
+4% +$8.64K ﹤0.01% 2621
2026
Q1 		$232K Sell
3,992
-3,806
-49% -$207K ﹤0.01% 2557
2025
Q4 		$363K Sell
7,798
-42,827
-85% -$1.92M ﹤0.01% 2443
2025
Q3 		$1.81M Buy
50,625
+31,409
+163% +$1.04M ﹤0.01% 1541
2025
Q2 		$628K Buy
19,216
+755
+4% +$24.8K ﹤0.01% 2038
2025
Q1 		$675K Buy
18,461
+552
+3% +$44.1K ﹤0.01% 1931
2024
Q4 		$1.45M Buy
17,909
+4,443
+33% +$441K ﹤0.01% 1614
2024
Q3 		$1.53M Sell
13,466
-480
-3% -$43.3K ﹤0.01% 1528
2024
Q2 		$1.05M Buy
+13,946
New +$949K ﹤0.01% 1664

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

HSBC Holdings's PCVX Position: Q2 2026 in Review

HSBC Holdings increased its Vaxcyte (PCVX) stake by 4% in Q2 2026, buying an estimated $8.64K and bringing the position to 4,151 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #2621.

HSBC Holdings first reported a position in PCVX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.81M in Q3 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • HSBC Holdings held 4,151 shares of Vaxcyte worth $241K as of Q2 2026.
  • HSBC Holdings bought 159 Vaxcyte shares in Q2 2026, an estimated $8.64K.
  • Vaxcyte made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2621 holding.
  • HSBC Holdings first reported a position in Vaxcyte in Q2 2024 and has held it in 9 quarters since.
  • HSBC Holdings's Vaxcyte position peaked at $1.81M in Q3 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.